Your browser doesn't support javascript.
loading
European Respiratory Society guideline on various aspects of quality in lung cancer care.
Blum, Torsten Gerriet; Morgan, Rebecca L; Durieux, Valérie; Chorostowska-Wynimko, Joanna; Baldwin, David R; Boyd, Jeanette; Faivre-Finn, Corinne; Galateau-Salle, Françoise; Gamarra, Fernando; Grigoriu, Bogdan; Hardavella, Georgia; Hauptmann, Michael; Jakobsen, Erik; Jovanovic, Dragana; Knaut, Paul; Massard, Gilbert; McPhelim, John; Meert, Anne-Pascale; Milroy, Robert; Muhr, Riccardo; Mutti, Luciano; Paesmans, Marianne; Powell, Pippa; Putora, Paul Martin; Rawlinson, Janette; Rich, Anna L; Rigau, David; de Ruysscher, Dirk; Sculier, Jean-Paul; Schepereel, Arnaud; Subotic, Dragan; Van Schil, Paul; Tonia, Thomy; Williams, Clare; Berghmans, Thierry.
Afiliação
  • Blum TG; Department of Pneumology, Lungenklinik Heckeshorn, HELIOS Klinikum Emil von Behring, Berlin, Germany.
  • Morgan RL; Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, ON, Canada.
  • Durieux V; Bibliothèque des Sciences de la Santé, Université Libre de Bruxelles (ULB), Brussels, Belgium.
  • Chorostowska-Wynimko J; Department of Genetics and Clinical Immunology, National Institute of Tuberculosis and Lung Diseases, Warsaw, Poland.
  • Baldwin DR; Department of Respiratory Medicine, Nottingham University Hospitals, Nottingham, UK.
  • Boyd J; European Lung Foundation, Sheffield, UK.
  • Faivre-Finn C; Division of Cancer Sciences, University of Manchester and The Christie NHS Foundation Trust, Manchester, UK.
  • Galateau-Salle F; Department of Biopathology, MESOPATH/MESOBANK Cancer Center Leon Berard, Lyon, France.
  • Gamarra F; Sektion Pneumologie, Klinikum St Elisabeth, Straubing, Germany.
  • Grigoriu B; Intensive Care and Oncological Emergencies and Thoracic Oncology, Institut Jules Bordet, Centre des Tumeurs de l'Université Libre de Bruxelles (ULB), Brussels, Belgium.
  • Hardavella G; Department of Respiratory Medicine, King's College Hospital London, London, UK.
  • Hauptmann M; Department of Respiratory Medicine and Allergy, King's College London, London, UK.
  • Jakobsen E; Institute of Biostatistics and Registry Research, Brandenburg Medical School Theodor Fontane and Faculty of Health Sciences Brandenburg, Neuruppin, Germany.
  • Jovanovic D; Department of Thoracic Surgery, Odense University Hospital, Odense, Denmark.
  • Knaut P; Internal Medicine Clinic "Akta Medica", Belgrade, Serbia.
  • Massard G; Department of Pneumology, Lungenklinik Heckeshorn, HELIOS Klinikum Emil von Behring, Berlin, Germany.
  • McPhelim J; Faculty of Science, Technology and Medicine, University of Luxembourg and Department of Thoracic Surgery, Hôpitaux Robert Schuman, Luxembourg, Luxembourg.
  • Meert AP; Lung Cancer Nurse Specialist, Hairmyres Hospital, NHS Lanarkshire, East Kilbride, UK.
  • Milroy R; Intensive Care and Oncological Emergencies and Thoracic Oncology, Institut Jules Bordet, Centre des Tumeurs de l'Université Libre de Bruxelles (ULB), Brussels, Belgium.
  • Muhr R; Scottish Lung Cancer Forum, Glasgow Royal Infirmary, Glasgow, UK.
  • Mutti L; Department of Pneumology, Lungenklinik Heckeshorn, HELIOS Klinikum Emil von Behring, Berlin, Germany.
  • Paesmans M; Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, L'Aquila, Italy.
  • Powell P; SHRO/Temple University, Philadelphia, PA, USA.
  • Putora PM; Data Centre, Institut Jules Bordet, Université Libre de Bruxelles (ULB), Brussels, Belgium.
  • Rawlinson J; European Lung Foundation, Sheffield, UK.
  • Rich AL; Departments of Radiation Oncology, Kantonsspital St Gallen, St Gallen and University of Bern, Bern, Switzerland.
  • Rigau D; European Lung Foundation Patient Advisory Group, Sandwell, UK.
  • de Ruysscher D; Department of Respiratory Medicine, Nottingham University Hospitals, Nottingham, UK.
  • Sculier JP; Iberoamerican Cochrane Center, Barcelona, Spain.
  • Schepereel A; Maastricht University Medical Center, Department of Radiation Oncology (Maastro Clinic), GROW School for Oncology and Developmental Biology, Maastricht, The Netherlands.
  • Subotic D; Erasmus Medical Center, Department of Radiation Oncology, Rotterdam, The Netherlands.
  • Van Schil P; Intensive Care and Oncological Emergencies and Thoracic Oncology, Institut Jules Bordet, Centre des Tumeurs de l'Université Libre de Bruxelles (ULB), Brussels, Belgium.
  • Tonia T; Pulmonary and Thoracic Oncology, Université de Lille, Inserm, CHU Lille, Lille, France.
  • Williams C; Clinic for Thoracic Surgery, University Hospital Zurich, Zurich, Switzerland.
  • Berghmans T; Department of Thoracic and Vascular Surgery, Antwerp University Hospital, Edegem, Belgium.
Eur Respir J ; 61(2)2023 02.
Article em En | MEDLINE | ID: mdl-36396145
ABSTRACT
This European Respiratory Society guideline is dedicated to the provision of good quality recommendations in lung cancer care. All the clinical recommendations contained were based on a comprehensive systematic review and evidence syntheses based on eight PICO (Patients, Intervention, Comparison, Outcomes) questions. The evidence was appraised in compliance with the GRADE (Grading of Recommendations Assessment, Development and Evaluation) approach. Evidence profiles and the GRADE Evidence to Decision frameworks were used to summarise results and to make the decision-making process transparent. A multidisciplinary Task Force panel of lung cancer experts formulated and consented the clinical recommendations following thorough discussions of the systematic review results. In particular, we have made recommendations relating to the following quality improvement measures deemed applicable to routine lung cancer care 1) avoidance of delay in the diagnostic and therapeutic period, 2) integration of multidisciplinary teams and multidisciplinary consultations, 3) implementation of and adherence to lung cancer guidelines, 4) benefit of higher institutional/individual volume and advanced specialisation in lung cancer surgery and other procedures, 5) need for pathological confirmation of lesions in patients with pulmonary lesions and suspected lung cancer, and histological subtyping and molecular characterisation for actionable targets or response to treatment of confirmed lung cancers, 6) added value of early integration of palliative care teams or specialists, 7) advantage of integrating specific quality improvement measures, and 8) benefit of using patient decision tools. These recommendations should be reconsidered and updated, as appropriate, as new evidence becomes available.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Pulmão / Neoplasias Pulmonares Tipo de estudo: Guideline / Prognostic_studies / Qualitative_research Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Pulmão / Neoplasias Pulmonares Tipo de estudo: Guideline / Prognostic_studies / Qualitative_research Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article